{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT05879978","nct_id":"NCT05879978","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05879978. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Successive cohorts of patients will receive increasing doses of obrixtamig in combination with ezabenlimab until the maximum tolerated dose (MTD) is reached, or upon decision of Dose Escalation Committee (DEC).","label":"obrixtamig + ezabenlimab treatment group","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-03-31","type":"ESTIMATED"},"conditions":["Small Cell Lung Carcinoma (SCLC)","Neuroendocrine Neoplasms"],"enrollment":{"count":45,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Obrixtamig","type":"DRUG"},{"name":"Ezabenlimab","type":"DRUG"}],"last_update":"2026-08-04","lead_sponsor":"Boehringer Ingelheim","official_title":"A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2025-06-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period","timeFrame":"up to 19 months"}],"references":[],"start_date":{"date":"2023-06-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","url":"https://clinicaltrials.gov/study/NCT05879978"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05879978"}